| Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia -> Monitor Keywords |
|
|
 
Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimiaRelated Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Designated Organic Active Ingredient Containing (doai), Peptide Containing (e.g., Protein, Peptones, Fibrinogen, Etc.) Doai, Insulin Or DerivativeSoluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20060287221, Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia. Brief Patent Description - Full Patent Description - Patent Application Claims
CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of International Application serial no. PCT/DK2004/000788 filed Nov. 12, 2004 and claims priority from Danish Application serial no. PA 2003 01689 filed Nov. 13, 2003 and of U.S. provisional application Ser. No. 60/519,590 filed on Nov. 13, 2003. FIELD OF THE INVENTION [0002] The present invention relates to the field of pharmaceutical compositions. More specifically the invention pertains to pharmaceutical compositions comprising two different pharmaceutically active peptides. BACKGROUND OF THE INVENTION [0003] Diabetes mellitus is a metabolic disorder in which the ability to utilize glucose is partly or completely lost. About 5% of all people suffer from diabetes and the disorder approaches epidemic proportions. Since the introduction of insulin in the 1920's, continuous efforts have been made to improve the treatment of diabetes mellitus. Since people suffering from diabetes are subject to chronic treatment over several decades, there is a major need for safe, convenient and life quality improving insulin formulations. [0004] In the treatment of diabetes mellitus, many varieties of insulin formulations have been suggested and used, such as regular insulin, isophane insulin (designated NPH), insulin zinc suspensions (such as Semilente.RTM., Lente.RTM., and Ultralente.RTM.), and biphasic isophane insulin. Some of the commercial available insulin formulations are characterized by a fast onset of action and other formulations have a relatively slow onset but show a more or less prolonged action. Fast-acting insulin formulations are usually solutions of insulin, while retarded acting insulin formulations can be suspensions containing insulin in crystalline and/or amorphous form precipitated by addition of zinc salts alone or by addition of protamine or by a combination of both. [0005] Normally, insulin formulations are administered by subcutaneous injection. What is important for the patient is the action profile of the insulin formulation which is the action of insulin on the glucose metabolism as a function of the time from the injection. In this profile, inter alia, the time for the onset, the maximum value, and the total duration of action are important. A variety of insulin formulations with different action profiles are desired and requested by the patients. [0006] Human insulin consists of two polypeptide chains, the so-called A and B chains which contain 21 and 30 amino acid residues, respectively. The A and B chains are interconnected by two cystine disulphide bridges. Insulin from most other species has a similar construction, but may not contain the same amino acid residues at the same positions. Within the last decade a number of human insulin analogues have been developed. They are designed for particular profiles of action, i.e. fast acting or prolonged action. [0007] Another peptide expected to become very important in the treatment of diabetes is glucagon-like peptide-1 (GLP-1). Human GLP-1 is a 37 amino acid residue peptide originating from preproglucagon which is synthesized i.a. in the L-cells in the distal ileum, in the pancreas and in the brain. GLP-1 is an important gut hormone with regulatory function in glucose metabolism and gastrointestinal secretion and metabolism. GLP-1 stimulates insulin secretion in a glucose-dependant manner, stimulates insulin biosynthesis, promotes beta cell rescue, decreases glucagon secretion, gastric emptying and food intake. A simple system is used to describe fragments and analogues of this peptide. Thus, for example, Gly.sup.8-GLP-1(7-37) designates an analogue of GLP-1(7-37) formally derived from GLP-1(7-37) by substituting the naturally occurring amino acid residue in position 8 (Ala) by Gly. Similarly, Lys.sup.34(N.sup..epsilon.-tetradecanoyl)-GLP-1(7-37) designates GLP-1(7-37) wherein the .epsilon.-amino group of the Lys residue in position 34 has been tetradecanoylated. PCT publications WO 98/08871 and WO 99/43706 disclose stable derivatives of GLP-1 analogues, which have a lipophilic substituent. These stable derivatives of GLP-1 analogues have a protracted profile of action compared to the corresponding GLP-1 analogues. [0008] As the type 2 diabetes population is rapidly increasing in the world, there is a much larger need for simpler administration of more effective drugs. The combined effects of GLP-1 are expected to give very effective and safe lowering of blood glucose. However, some patients may benefit from an extra small dose of insulin with the main meals. A combination formulation comprising an insulin peptide and a GLP-1 peptide, may with a fixed ratio of the two pharmaceuticals, be a very efficacious treatment as well as one requiring less injections when administered to the same patient. Because only a low dose of insulin is given with the meal and the GLP-1 counterpart of the formulation controls glucose for the rest of the day and night, and since GLP-1 does not lead to hypoglycaemia it may also be a very safe treatment. [0009] Thus, there is a big need for stable pharmaceutical compositions comprising meal-related insulin and a GLP-1 peptide in one combined formulation. BREIF DESCRIPTION OF THE DRAWINGS [0010] FIG. 1. Average disappearance curves showing the disappearance of radiolabeled insulin aspart. [0011] FIG. 2. Plasma levels of liraglutide after subcutaneous injections of the mixtures (logarithmic scale). [0012] FIG. 3. Plasma levels of liraglutide after subcutaneous injections of the mixtures (linear scale). [0013] FIG. 4. Turbidimetric measurements of two pharmaceutical compositions containing aspart and liraglutide. Pharmaceutical composition without poloxamer 188 (x) and with poloxamer 188 (.diamond.) (500 ppm). [0014] FIG. 5. Turbidimetric measurements of two pharmaceutical compositions containing aspart and liraglutide. Pharmaceutical composition without poloxamer 188 (x) and with poloxamer 188 (.diamond.) (50 ppm). [0015] FIG. 6. All samples contain: 0.6 mM insulin aspart, 0.3 mM Zn(Ac).sub.2, 1.2 mM Liraglutide, 14 mg/ml propylene glycol, 40 mM phenol, 10 mM NaCl, pH 7.7. Poloxamer 188 is added to two of the samples. [0016] FIG. 7. Both samples contain 0.6 mM insulin aspart, 0.3 mM Zn(Ac).sub.2, 1.2 mM Liraglutide, 40 mM phenol, 14 mg/ml propylene glycol, 10 mM NaCl, pH 7.7. Polysorbate 20 is added to one sample. [0017] FIG. 8. All samples contain 0.6 mM insulin aspart, 0.3 mM Zn(Ac).sub.2, 1.2 mM Liraglutide, 8 mM sodium phosphate pH 7.7, 40 mM phenol, 14 mg/ml propylene glycol. Poloxamer 188 is added to two samples. [0018] FIG. 9. 0.6 mM insulin aspart, 0.3 mM Zn(Ac).sub.2, 1.2 mM Liraglutide, 8 mM sodium phosphosfate, 40 mM phenol, 14 mg/ml propylene glycol, pH 7.7. Polysorbate 20 is added to two of the samples. SUMMARY OF THE INVENTION [0019] One object of the present invention is to provide a soluble pharmaceutical composition for parenteral administration, which comprises an insulinotropic peptide, a meal related insulin peptide, a pharmaceutically acceptable preservative and optionally an isotonicity agent. In one embodiment of the invention, pH of said pharmaceutical composition or a reconstituted solution of said pharmaceutical composition is from about pH 7.0 to about pH 9.0. In another embodiment of the invention, pH of said pharmaceutical composition or a reconstituted solution of said pharmaceutical composition is from about pH 7.0 to about pH 8.0. Continue reading about Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia... Full patent description for Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia or other areas of interest. ### Previous Patent Application: Water soluble paclitaxel prodrugs Next Patent Application: Polymerized hemoglobin solutions having reduced amounts of tetramer and method for preparing Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia patent info. IP-related news and info Results in 0.164 seconds Other interesting Feshpatents.com categories: Computers: Graphics , I/O , Processors , Dyn. Storage , Static Storage , Printers 174 |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
